



Supplementary Figure 1. Initial imaging.




Supplementary Figure 1. Initial imaging. S1a. CXR on 4/21/2020 demonstrating basilar predominant bilateral airspace disease (right greater than left) consistent with viral pneumonia. Cavitory change is apparent on the right (arrow). Note, no pneumothorax is present. **S1b.** Axial section of CTA chest on 4/22/2020 demonstrating large right pneumothorax (asterisk) and a RLL cavitory lesion (green box).

Supplementary Figure 2. Catheter thoracostomy treatment.




Supplementary Figure 2. Catheter thoracostomy treatment. S2a. Resolution of PTX with 14 Fr. Pigtail catheter thoracostomy (arrow). **S2b.** CXR demonstrating well-expanded right lung after thoracostomy tube removal.

Supplementary Figure 3. RUL cavitory lesion.



Supplementary Figure 3. RUL cavitory lesion. S3a. Coronal section of CTA chest 4/22/2020 (Day 1) demonstrating a complex RUL cavitory lesion (green box, 3D model inset). **S3b.** Coronal section of CTA chest on 4/27/2020 (Day 5) demonstrating decreased size of the RUL cavity (green box) and corresponding 3D model of the cavity (purple, inset).


Supplementary Figure 4. Interval CT imaging, Day 54.



Supplementary Figure 4. 4a. CT thorax Day 54: Ongoing resolution of RLL cavity. **4b.** CT thorax Day 54: Small RUL cavity and 3D model. Note: Green boxes indicate cavities. 3D models (purple) are scaled for comparison between panels.

Supplementary Figure 5. Pulmonary Function Testing

| Pulmonary Function Parameters Measured | | | | |
|----------------------------------------|-------|-------|----------|-------|
| | LLN | Pred | Baseline | %Pred |
| FVC | 4.89 | 6.10 | 5.49 | 90 |
| FEV1 | 3.90 | 4.91 | 4.56 | 93 |
| FEV1/FVC | 70 | 81 | 83 | |
| PEF | 8.58 | 11.17 | 10.22 | 91 |
| FEF 25/75 | 2.84 | 4.73 | 4.48 | 95 |
| FET | | | 8.46 | |
| V backextrap. | | | 0.12 | |
| SVQ | 4.89 | 6.10 | 5.49 | 90 |
| IC | | 4.21 | 3.85 | 91 |
| ERV | | 1.62 | 1.64 | 101 |
| RV | 1.33 | 2.00 | 1.70 | 85 |
| FRCpl | 2.64 | 3.62 | 3.34 | 92 |
| TLC | 6.79 | 7.94 | 7.18 | 91 |
| RV%TLC | 19 | 28 | 24 | 86 |
| RAW .71-2.60 | | | 2.38 | |
| GAW .38-1.4 | | | 0.42 | |
| sGAW >.10 | | | 0.13 | |
| DLCO SB | 28.03 | 35.83 | 33.68 | 94 |
| DLVA | 3.72 | 4.71 | 5.31 | 113 |
| VA SB | 6.27 | 7.66 | 6.34 | 83 |
| IVC_SB | 4.91 | 5.84 | 5.28 | 91 |



Supplementary Figure 5. Pulmonary Function Testing. Convalescent pulmonary function testing was obtained on June 16, 2020. There is no pulmonary function testing prior to the COVID-19 infection.

Supplementary Table 1. Basic laboratory values

| <u>Test</u> | <u>Outcome</u> |
|------------------------|----------------------------|
| White blood cell count | 8.6 |
| Hemoglobin | 15.7 |
| Platelet count | 268 |
| Sodium | 139 |
| Potassium | 3.9 |
| Blood urea nitrogen | 14 |
| Creatinine | 1.01 |
| Glucose | 93 |
| Magnesium | 1.9 |
| Phosphate | 2.5 |
| Lactate | 2.1 (normal <2) |
| Troponin | 0.01 (normal <0.03 ng/mL) |
| Procalcitonin | 0.03 (normal <0.25 ng/mL) |
| C-reactive protein | 2.6 (normal 0.0-1.0 mg/dL) |

Supplementary Table 1. Basic laboratory values. Basic laboratory evaluation on April 22nd, 2020 was unremarkable. Notably, there was no leukocytosis and the procalcitonin was normal.

Supplementary Table 2. Cavity Volumes

| Date of CT chest | Cavitary Lesion | Volume (mm³) |
|-------------------------|------------------------|--------------------------------|
| 4/22/2020 | RLL | 20479 |
| 4/22/2020 | RUL | 6816 |
| 4/22/2020 | LLL | 402 |
| 4/27/2020 | RLL | 30057 |
| 4/27/2020 | RUL | 941 |
| 4/27/2020 | LLL | 125 |
| 5/27/2020 | RLL | 1618 |
| 6/15/2020 | RLL | 135 |
| 6/15/2020 | RUL | 34 |

Supplementary Table 2. Cavity volumes. 3D models of the cavities were generated using Mimics; 3-matic; Materialise (Leuven, Belgium) software and cavity volumes (mm³) were measured.